Cellectis S.A (CLLS)

[Frankestin]

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

* UCART22: ANTI-TUMOR ACTIVITY OBSERVED IN 60% (N=3) OF PATIENTS AT DL3 USING FCA LYMPHODEPLETION
* AMELI-01 STUDY (EVALUATING UCART123) NOW ENROLLING PATIENTS IN A TWO-DOSE REGIMEN ARM AT DL2
* UCART123: 25% (N=2) OF PATIENTS AT DL2 IN FCA ARM ACHIEVED MEANINGFUL RESPONSE
* NEXT DATA SET IS EXPECTED TO BE RELEASED IN 2023
* UCART123: ONE PATIENT EXPERIENCED A DURABLE MINIMAL RESIDUAL DISEASE (MRD)-NEGATIVE COMPLETE RESPONSE THAT CONTINUES BEYOND 12 MONTHS


dry hands still sell